Thrombin specificity. Requirement for apolar amino accleavage site of polypeptide substrate

FEBS Journal

151, 217-224

DOI: 10.1111/j.1432-1033.1985.tb09091.x

Citation Report

#	Article	IF	CITATIONS
1	Thrombin specificity. Selective cleavage of antibody light chains at the joints of variable with joining regions and joining with constant regions. FEBS Journal, 1985, 151, 225-230.	0.2	25
2	Proteolytic Derivatives of Thrombin. Annals of the New York Academy of Sciences, 1986, 485, 16-26.	3.8	31
3	Abolition of ATPase activities of skeletal myosin subfragment 1 by a new selective proteolytic cleavage within the 50-kilodalton heavy chain segment. Biochemistry, 1986, 25, 1134-1140.	2.5	42
4	The structures and proteolytic specificities of autolysed human thrombin. Biochemical Journal, 1986, 240, 797-802.	3.7	67
5	Chapter 7 Fibrinogen, fibrin and factor XIII. New Comprehensive Biochemistry, 1986, , 171-241.	0.1	66
6	Chemical modification of the carboxyl groups of protein substrates enhances their thrombin susceptibility. FEBS Letters, 1987, 222, 6-10.	2.8	O
7	Highly sensitive peptide-4-methylcoumaryl-7-amide substrates for blood-clotting proteases and trypsin. FEBS Journal, 1988, 172, 17-25.	0.2	235
8	The isolation and characterisation of human atrial natriuretic factor produced as a fusion protein in Escherichia coli. FEBS Journal, 1988, 174, 405-410.	0.2	20
9	A complete quantitative N-terminal analysis method. Analytical Biochemistry, 1988, 170, 542-556.	2.4	34
10	Thrombin inactivates acidic fibroblast growth factor but not basic fibroblast growth factor. Biochemistry, 1988, 27, 2572-2578.	2.5	78
11	On the two types of the thrombin high molecular substrates. Thrombosis Research, 1988, 49, 303-304.	1.7	3
12	Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase. Gene, 1988, 67, 31-40.	2.2	6,310
13	Development of a monoclonal antibody against recombinant neuroendocrine 7B2 protein. FEBS Letters, 1989, 255, 372-376.	2.8	15
14	Preparation of monoclonal antibodies to hirudin and hirudin peptides. A method for studying the hirudin-thrombin interaction. FEBS Journal, 1990, 188, 463-470.	0.2	21
15	Recombinant human protein C derivatives: altered response to calcium resulting in enhanced activation by thrombin EMBO Journal, 1990, 9, 2367-2373.	7.8	45
16	The structure of a complex of recombinant hirudin and human alpha-thrombin. Science, 1990, 249, 277-280.	12.6	781
17	Antithrombin activity of the hirudin N-terminal core domain residues 1-43. FEBS Letters, 1990, 260, 209-212.	2.8	20
	The structural elements of hirudin which bind to the fibrinogen recognition site of thrombin are		

#	Article	IF	Citations
19	Inhibition of thrombin by synthetic hirudin peptides. FEBS Letters, 1990, 270, 85-89.	2.8	11
20	cDNA cloning and expression of a hamster αâ€thrombin receptor coupled to Ca ²⁺ mobilization. FEBS Letters, 1991, 288, 123-128.	2.8	441
21	Refined structure of the Hirudin-thrombin complex. Journal of Molecular Biology, 1991, 221, 583-601.	4.2	378
22	General synthesis of polyfunctionalized fluoromethyleneketone retroamides as potential inhibitors of thrombin. Tetrahedron Letters, 1991, 32, 7255-7258.	1.4	48
23	Thrombin cleavage analysis of a novel antihaemophilic factor variant, factor VIII Delta II. FEBS Journal, 1991, 195, 637-644.	0.2	6
24	Eukaryotic proteins expressed in Escherichia coli: An improved thrombin cleavage and purification procedure of fusion proteins with glutathione S-transferase. Analytical Biochemistry, 1991, 192, 262-267.	2.4	1,880
25	Thrombin and H64A subtilisin cleavage of fusion proteins for preparation of human recombinant parathyroid hormone. The Protein Journal, 1991, 10, 517-526.	1.1	31
26	Glu-192Gln substitution in thrombin mimics the catalytic switch induced by thrombomodulin Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 7371-7375.	7.1	159
27	Ligation-independent cloning of glutathione fusion genes for expression in Escherichia coli. Gene, 1992, 112, 37-43.	2.2	52
28	An evaluation of different enzymatic cleavage methods for recombinant fusion proteins, applied on des (1?3) insulin-like growth factor I. The Protein Journal, 1992, 11, 201-211.	1.1	43
29	Efficient expression and purification of a protease from the common cold virus, human rhinovirus type 14. Journal of Crystal Growth, 1992, 122, 246-252.	1.5	13
30	New vectors for high level expression of recombinant proteins in bacteria. Analytical Biochemistry, 1992, 202, 293-298.	2.4	259
31	Peptide Stability in Drug Development: A Comparison of Peptide Reactivity in Different Biological Media. Journal of Pharmaceutical Sciences, 1992, 81, 731-735.	3.3	101
32	Production and characterization of recombinant turkey prolactin. Comparative Biochemistry and Physiology Part B: Comparative Biochemistry, 1993, 106, 273-280.	0.2	9
33	Recombinant fel d I: expression, purification, IgE binding and reaction with cat-allergic human T cells. Molecular Immunology, 1993, 30, 559-568.	2.2	49
34	[21] Protein C activation. Methods in Enzymology, 1993, 222, 359-385.	1.0	62
35	NonO, a non-POU-domain-containing, octamer-binding protein, is the mammalian homolog of Drosophila nonAdiss Molecular and Cellular Biology, 1993, 13, 5593-5603.	2.3	99
36	Identification of a region of beta 2-glycoprotein I critical for lipid binding and anti-cardiolipin antibody cofactor activity Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 2141-2145.	7.1	176

#	ARTICLE	IF	CITATIONS
37	The MAP kinase Fus3 associates with and phosphorylates the upstream signaling component Ste5 Genes and Development, 1994, 8, 313-327.	5.9	126
38	Efficient and Rapid Affinity Purification of Proteins Using Recombinant Fusion Proteases. Nature Biotechnology, 1994, 12, 601-605.	17.5	133
39	Enzymatic and Chemical Cleavage of Fusion Proteins. Current Protocols in Molecular Biology, 1994, 28, Unit16.4B.	2.9	11
40	Conformational rearrangements required of the V3loop of HIV-1 gp120 for proteolytic cleavage and infection. FEBS Letters, 1994, 337, 4-8.	2.8	31
41	Amidase activity and thermal stability of human thrombin. Applied Biochemistry and Biotechnology, 1994, 48, 125-135.	2.9	11
42	Design and Evaluation of a Thrombin-Activable Plasminogen Activator. Biochemistry, 1994, 33, 2306-2312.	2.5	22
43	Recombinant soluble human tissue factor secreted by <i>Saccharomyces cerevisiae</i> and refolded from <i>Escherichia coli</i> inclusion bodies: glycosylation of mutants, activity and physical characterization. Biochemical Journal, 1995, 310, 605-614.	3.7	88
44	Molecular Cloning, Functional Expression in Escherichia coli, and Characterization of Multiple Mitogen-Activated-Protein Kinases from Tobacco. FEBS Journal, 1995, 233, 249-257.	0.2	67
45	Production of Recombinant Bovine Enterokinase Catalytic Subunit in Escherichia coli Using the Novel Secretory Fusion Partner DsbA. Nature Biotechnology, 1995, 13, 982-987.	17.5	97
46	Preparation of soluble recombinant T cell receptor α chain by using a calmodulin fusion expression system. Journal of Immunological Methods, 1995, 186, 27-36.	1.4	8
47	McrB: a prokaryotic protein specifically recognizing DNA containing modified cytosine residues EMBO Journal, 1995, 14, 2661-2669.	7.8	40
48	Structure/Function Aspects of Neutral P1 Residue Peptide Inhibitors of Thrombin. Journal of Enzyme Inhibition and Medicinal Chemistry, 1995, 9, 29-41.	0.5	11
49	Human Mast Cell Chymase and Leukocyte Elastase Release Latent Transforming Growth Factor- \hat{l}^21 from the Extracellular Matrix of Cultured Human Epithelial and Endothelial Cells. Journal of Biological Chemistry, 1995, 270, 4689-4696.	3.4	353
50	Cloning, expression and characterization of biologically active feline tumour necrosis factor-α. Veterinary Immunology and Immunopathology, 1995, 45, 297-310.	1.2	23
51	Initiation of protein synthesis by the eukaryotic translational apparatus on circular RNAs. Science, 1995, 268, 415-417.	12.6	629
52	Stonustoxin Is a Novel Lethal Factor from Stonefish (Synanceja horrida) Venom. Journal of Biological Chemistry, 1996, 271, 25575-25581.	3.4	77
53	Shifts in the Thrombin: Protease Nexin I Balance in Postnatal and Degenerative Synapse Elimination. Advances in Organ Biology, 1997, 2, 351-375.	0.1	2
54	THROMBIN INTERACTION WITH FIBRIN POLYMERIZATION SITES. Thrombosis Research, 1997, 86, 301-316.	1.7	24

#	Article	IF	CITATIONS
55	Thrombin cleaves recombinant human thrombopoietin: One of the proteolytic events that generates truncated forms of thrombopoietin. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 4669-4674.	7.1	37
56	A Novel Degradation Pathway of Tissue Factor Pathway Inhibitor: Incorporation Into Fibrin Clot and Degradation by Thrombin. Blood, 1997, 90, 1883-1892.	1.4	42
57	A Simple and Rapid Method for Purifying the Extracellular Domain of Human Tissue Factor. Thrombosis Research, 1998, 91, 249-253.	1.7	4
58	Role of Immunoglobulin-like Domains 2–4 of the Platelet-derived Growth Factor α-Receptor in Ligand-Receptor Complex Assembly. Journal of Biological Chemistry, 1998, 273, 25495-25502.	3.4	17
59	Clinical status of direct thrombin inhibitors. Critical Reviews in Oncology/Hematology, 1999, 31, 97-117.	4.4	8
60	Contribution of kinases and the CD45 phosphatase to the generation of tyrosine phosphorylation patterns in the T-cell receptor complex $\hat{\mathbf{q}}$ chain. Immunology Letters, 1999, 67, 31-39.	2.5	16
61	The Use of Recombinant Fusion Proteases in the Affinity Purification of Recombinant Proteins. Molecular Biotechnology, 1999, 12, 269-274.	2.4	16
62	The terminal structure plays an important role in the biological activity of cecropin CMIV. Science in China Series C: Life Sciences, 1999, 42, 494-500.	1.3	1
63	Reactivity of Lys(NH2)-containing peptides toward endopeptidases., 1999, 5, 352-359.		5
64	Cloning and expression of Der f 6, a serine protease allergen from the house dust mite, Dermatophagoides farinae1The sequence data reported in this paper have been deposited in the GenBank Sequence Database under accession No. AF125187.1. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 1999, 1454, 201-207.	3.8	18
65	Circular \hat{l}^2 -lactamase: stability enhancement by cyclizing the backbone. FEBS Letters, 1999, 459, 166-172.	2.8	175
66	Overexpression, Oxidative Refolding, and Zinc Binding of Recombinant Forms of the Murine S100 Protein MRP14 (S100A9). Protein Expression and Purification, 1999, 15, 228-235.	1.3	19
67	Examining Thrombin Hydrolysis of the Factor XIII Activation Peptide Segment Leads to a Proposal for Explaining the Cardioprotective Effects Observed with the Factor XIII V34L Mutation. Journal of Biological Chemistry, 2000, 275, 20627-20631.	3.4	64
68	E.coli Expression Systems. , 0, , 461-490.		0
69	Specificity Assay of Serine Proteinases by Reverse-Phase High-Performance Liquid Chromatography Analysis of Competing Oligopeptide Substrate Library. Analytical Biochemistry, 2001, 288, 156-167.	2.4	33
70	A Novel Purification Method for Histidine-Tagged Proteins Containing a Thrombin Cleavage Site. Analytical Biochemistry, 2001, 295, 180-185.	2.4	59
71	Fragile T-stem in Disease-associated Human Mitochondrial tRNA Sensitizes Structure to Local and Distant Mutations. Journal of Biological Chemistry, 2001, 276, 10607-10611.	3.4	37
72	Biologically Active Recombinant Human Progastrin6–80Contains a Tightly Bound Calcium Ion. Journal of Biological Chemistry, 2001, 276, 7791-7796.	3.4	61

#	Article	IF	Citations
73	C1 Inhibitor: Analysis of the Role of Amino Acid Residues Within the Reactive Center Loop in Target Protease Recognition. Journal of Immunology, 2001, 167, 1500-1506.	0.8	14
74	Pronatriuretic peptide is a sensitive marker of the endocrine function of teleost heart. American Journal of Physiology - Endocrinology and Metabolism, 2002, 282, E843-E850.	3.5	4
75	Title is missing!. Biotechnology Letters, 2002, 24, 657-662.	2.2	5
76	Genetic design for facilitated production and recovery of recombinant proteins in Escherichia coli. Biotechnology and Applied Biochemistry, 2002, 35, 91.	3.1	103
77	Overview of tag protein fusions: from molecular and biochemical fundamentals to commercial systems. Applied Microbiology and Biotechnology, 2003, 60, 523-533.	3.6	1,153
78	Synthesis of 32P-labelled protein probes using a modified thioredoxin fusion protein expression system in Escherichia coli. New Biotechnology, 2003, 20, 1-5.	2.7	8
79	A critical review of the methods for cleavage of fusion proteins with thrombin and factor Xa. Protein Expression and Purification, 2003, 31, 1-11.	1.3	214
80	Recombinant Yersinia enterocolitica YscM1 and YscM2: homodimer formation and susceptibility to thrombin cleavage. Protein Expression and Purification, 2003, 31, 167-172.	1.3	12
81	Targeted Restoration of Cleavage in a Noncleaving Thyrotropin Receptor Demonstrates that Cleavage Is Insufficient to Enhance Ligand-Independent Activity. Endocrinology, 2003, 144, 1324-1330.	2.8	17
82	Molecular Heterogeneity Has a Major Impact on the Measurement of Circulating N-Terminal Fragments of A- and B-Type Natriuretic Peptides. Clinical Chemistry, 2004, 50, 1576-1588.	3.2	153
83	The von Willebrand factor-binding protein (vWbp) of <i>Staphylococcus aureus </i> is a coagulase. FEMS Microbiology Letters, 2004, 234, 309-314.	1.8	91
84	Tetracycline-regulated expression enables purification and functional analysis of recombinant connexin channels from mammalian cells. Biochemical Journal, 2004, 383, 111-119.	3.7	46
85	Proteolytic inactivation of ADAMTS13 by thrombin and plasmin. Blood, 2005, 105, 1085-1093.	1.4	217
86	Boundaries and physical characterization of a new domain shared between mammalian 53BP1 and yeast Rad9 checkpoint proteins. Protein Science, 2005, 14, 1827-1839.	7.6	13
87	Proteolysis of Non-phosphorylated and Phosphorylated Tau by Thrombin. Journal of Biological Chemistry, 2005, 280, 5145-5153.	3.4	65
88	Expression and characterization of N-terminal domain of Epstein–Barr virus latent membrane protein 2A in Escherichia coli. Protein Expression and Purification, 2005, 41, 9-17.	1.3	4
89	Heteropoda toxin 2 is a gating modifier toxin specific for voltage-gated K+ channels of the Kv4 family. Toxicon, 2005, 45, 431-442.	1.6	42
90	Novel recognition sequence of coxsackievirus 2A proteinase. Biochemical and Biophysical Research Communications, 2006, 348, 1436-1442.	2.1	6

#	Article	IF	CITATIONS
91	Investigation ofde novo Totally Random Biosequences, Part I. Chemistry and Biodiversity, 2006, 3, 827-839.	2.1	30
92	Recombinant Protein Techniques. , 2005, , 385-430.		0
93	Stability of a Receptor-Binding Active Human Immunodeficiency Virus Type 1 Recombinant gp140 Trimer Conferred by Intermonomer Disulfide Bonding of the V3 Loop: Differential Effects of Protein Disulfide Isomerase on CD4 and Coreceptor Binding. Journal of Virology, 2007, 81, 4604-4614.	3.4	14
94	Production of Authentic SARS-CoV Mpro with Enhanced Activity: Application as a Novel Tag-cleavage Endopeptidase for Protein Overproduction. Journal of Molecular Biology, 2007, 366, 965-975.	4.2	221
95	Nâ€ŧerminal cysteinyl proteins can be prepared using thrombin cleavage. FEBS Letters, 2008, 582, 1163-1167.	2.8	31
96	Specific and efficient cleavage of fusion proteins by recombinant plum pox virus NIa protease. Protein Expression and Purification, 2008, 57, 153-162.	1.3	25
97	Physcomitrella HMGA-type proteins display structural differences compared to their higher plant counterparts. Biochemical and Biophysical Research Communications, 2008, 374, 653-657.	2.1	2
98	Direct comparison of fluorescence- and bioluminescence-based resonance energy transfer methods for real-time monitoring of thrombin-catalysed proteolytic cleavage. Biosensors and Bioelectronics, 2009, 24, 1164-1170.	10.1	42
99	Fluorous-based peptide microarrays for protease screening. Journal of Fluorine Chemistry, 2009, 130, 1042-1048.	1.7	21
100	Expression and purification of soluble E-Syt2: Low protein stability impedes tag removal. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2009, 877, 1643-1650.	2.3	2
101	Platelet Matrix Metalloprotease-1 Mediates Thrombogenesis by Activating PAR1 at a Cryptic Ligand Site. Cell, 2009, 137, 332-343.	28.9	218
102	Expression and purification of human TRPV1 in baculovirus-infected insect cells for structural studies. Protein Expression and Purification, 2009, 65, 38-50.	1.3	12
103	Isolation, purification, and study of properties of recombinant hepsin from Escherichia coli. Biochemistry (Moscow), 2010, 75, 866-872.	1.5	2
104	Strategies to Optimize Protein Expression in <i>E. coli</i> . Current Protocols in Protein Science, 2010, 61, Unit 5.24.1-29.	2.8	118
105	Tag Removal by Site-Specific Cleavage of Recombinant Fusion Proteins. Methods in Molecular Biology, 2011, 681, 349-367.	0.9	11
106	Interactions between GIPC–APPL and GIPC–TRP1 regulate melanosomal protein trafficking and melanogenesis in human melanocytes. Archives of Biochemistry and Biophysics, 2011, 508, 227-233.	3.0	11
107	Improved isolation and purification of functional human Fas receptor extracellular domain using baculovirus – silkworm expression system. Protein Expression and Purification, 2011, 80, 102-109.	1.3	5
108	An overview of enzymatic reagents for the removal of affinity tags. Protein Expression and Purification, 2011, 80, 283-293.	1.3	268

#	Article	IF	CITATIONS
109	Osteopontin Undergoes Polymerization in Vivo and Gains Chemotactic Activity for Neutrophils Mediated by Integrin $\hat{l}\pm9\hat{l}^21$. Journal of Biological Chemistry, 2011, 286, 11170-11178.	3.4	47
110	Quantification of Prothrombin in Human Plasma Amplified by Autocatalytic Reaction. Analytical Chemistry, 2012, 84, 2380-2387.	6.5	5
111	Incorporation of Thrombin Cleavage Peptide into a Protein Cage for Constructing a Protease-Responsive Multifunctional Delivery Nanoplatform. Biomacromolecules, 2012, 13, 4057-4064.	5.4	33
112	The Extended Cleavage Specificity of Human Thrombin. PLoS ONE, 2012, 7, e31756.	2.5	102
113	Recombinant protein expression and purification: A comprehensive review of affinity tags and microbial applications. Biotechnology Journal, 2012, 7, 620-634.	3.5	371
114	Matrix metalloproteases and PAR1 activation. Blood, 2013, 121, 431-439.	1.4	153
115	Challenges and opportunities in the purification of recombinant tagged proteins. Biotechnology Advances, 2014, 32, 366-381.	11.7	121
116	Thrombin-mediated degradation of parathyroid hormone in serum tubes. Clinica Chimica Acta, 2014, 437, 191-196.	1.1	9
117	Improved fusion tag cleavage strategies in the downstream processing of self-assembling virus-like particle vaccines. Food and Bioproducts Processing, 2014, 92, 143-151.	3.6	9
118	Decoy Plasminogen Receptor Containing a Selective Kunitz-Inhibitory Domain. Biochemistry, 2014, 53, 505-517.	2.5	4
119	Design and implementation of a high yield production system for recombinant expression of peptides. Microbial Cell Factories, 2014, 13, 65.	4.0	33
120	Affinity Tags in Protein Purification and Peptide Enrichment: An Overview. Methods in Molecular Biology, 2014, 1129, 147-168.	0.9	15
121	Promiscuity and Selectivity in Covalent Enzyme Inhibition: AÂSystematic Study of Electrophilic Fragments. Journal of Medicinal Chemistry, 2014, 57, 7590-7599.	6.4	134
122	Multifunctional Thrombinâ€Activatable Polymer Capsules for Specific Targeting to Activated Platelets. Advanced Materials, 2015, 27, 5153-5157.	21.0	73
123	Molecular Cloning, Heterologous Expression, and Functional Characterization of an NADPH-Cytochrome P450 Reductase Gene from Camptotheca acuminata, a Camptothecin-Producing Plant. PLoS ONE, 2015, 10, e0135397.	2.5	20
124	Characterization of thrombin derived from human recombinant prothrombin. Blood Coagulation and Fibrinolysis, 2015, 26, 545-555.	1.0	2
125	Acceleration of Proteolytic Activity Associated with Selection of Thiol Ligand Coatings on Quantum Dots. ACS Applied Materials & Samp; Interfaces, 2015, 7, 2535-2545.	8.0	43
126	Limited Proteolysis of Fibrinogen by Fibrinogenase from Echis multisquamatis Venom. Protein Journal, 2015, 34, 130-134.	1.6	4

#	Article	IF	CITATIONS
127	An Adaptive Biointerface from Selfâ€Assembled Functional Peptides for Tissue Engineering. Advanced Materials, 2015, 27, 3181-3188.	21.0	80
128	Biomimetic chimeric peptide-tethered hydrogels for human mesenchymal stem cell delivery. Colloids and Surfaces B: Biointerfaces, 2015, 136, 634-640.	5.0	1
129	Two-Site Internally Cooperative Mechanism for Enzyme Kinetics in a Hydrogel Forming Recombinant Protein. Biomacromolecules, 2015, 16, 3651-3656.	5.4	1
130	Biorheology of Platelet Activation in the Bloodstream Distal to Thrombus Formation. Cellular and Molecular Bioengineering, 2016, 9, 496-508.	2.1	6
131	An insight into fusion technology aiding efficient recombinant protein production for functional proteomics. Archives of Biochemistry and Biophysics, 2016, 612, 57-77.	3.0	58
132	More than just one: multiplicity of Hirudins and Hirudin-like Factors in the Medicinal Leech, Hirudo medicinalis. Molecular Genetics and Genomics, 2016, 291, 227-240.	2.1	39
133	Nanostructured bioluminescent sensor for rapidly detecting thrombin. Biosensors and Bioelectronics, 2016, 77, 83-89.	10.1	28
134	Spectroscopic detection of thrombin with peptides self-assembled on gold nanoparticles hybridized graphene oxide. Sensors and Actuators B: Chemical, 2017, 242, 443-449.	7.8	18
135	Electrochemical oxidation of thrombin on carbon screen printed electrodes. Russian Journal of Electrochemistry, 2017, 53, 97-102.	0.9	6
136	Optimization and Changes in the Mode of Proteolytic Turnover of Quantum Dot–Peptide Substrate Conjugates through Moderation of Interfacial Adsorption. ACS Applied Materials & District Substrate 2017, 9, 30359-30372.	8.0	20
137	Thrombinâ€Responsive Transcutaneous Patch for Autoâ€Anticoagulant Regulation. Advanced Materials, 2017, 29, 1604043.	21.0	90
138	Dynamics of Blood Flow and Thrombus Formation in a Multi-Bypass Microfluidic Ladder Network. Cellular and Molecular Bioengineering, 2017, 10, 16-29.	2.1	37
139	CdS quantum dots generated in-situ for fluorometric determination of thrombin activity. Mikrochimica Acta, 2019, 186, 657.	5.0	9
140	Production of Circularly Permuted Caspase-2 for Affinity Fusion-Tag Removal: Cloning, Expression in Escherichia coli, Purification, and Characterization. Biomolecules, 2020, 10, 1592.	4.0	22
141	Prediction of Molecular Mutations in Diffuse Low-Grade Gliomas using MR Imaging Features. Scientific Reports, 2020, 10, 3711.	3.3	36
142	Isolation and characterization of oligopeptides with vascular disease suppression effects derived from wheat gluten. Journal of Food Science and Technology, 2021, 58, 3504-3513.	2.8	3
143	Neuraminidase-associated plasminogen recruitment enables systemic spread of natural avian Influenza viruses H3N1. PLoS Pathogens, 2021, 17, e1009490.	4.7	4
144	Smart Responsive Microarray Patches for Transdermal Drug Delivery and Biological Monitoring. Advanced Healthcare Materials, 2021, 10, e2100996.	7.6	15

#	ARTICLE	IF	CITATIONS
145	Thrombin Cleaves Prolactin Into a Potent 5.6-kDa Vasoinhibin: Implication for Tissue Repair. Endocrinology, $2021,162,.$	2.8	11
146	X-Ray Crystal Structures of Human \hat{l}_{\pm} -Thrombin and of the Human Thrombin-Hirudin Complex. , 1992, , 3-61.		11
147	Hirudin Interactions with Thrombin. , 1992, , 219-256.		16
148	Thrombin Inhibition by Synthetic Hirudin Peptides. Advances in Experimental Medicine and Biology, 1990, 281, 177-183.	1.6	6
149	Molecular Basis for the Inhibition of Thrombin by Hirudin. Advances in Experimental Medicine and Biology, 1993, 340, 35-49.	1.6	10
151	The von Willebrand factor-binding protein (vWbp) of Staphylococcus aureus is a coagulase. FEMS Microbiology Letters, 2004, 234, 309-314.	1.8	54
152	Overexpression and purification of the carboxyl-terminal nucleotide-binding domain from mouse P-glycoprotein. Strategic location of a tryptophan residue Journal of Biological Chemistry, 1994, 269, 22983-22989.	3.4	69
153	Plasminogen mutants activated by thrombin. Potential thrombus-selective thrombolytic agents Journal of Biological Chemistry, 1994, 269, 15989-15992.	3.4	20
154	Activation of the zymogen of hepatocyte growth factor activator by thrombin Journal of Biological Chemistry, 1993, 268, 22927-22932.	3.4	186
155	Production, properties, and thrombin inhibitory mechanism of hirudin amino-terminal core fragments Journal of Biological Chemistry, 1990, 265, 22159-22166.	3.4	35
156	Purification and characterization of the carboxyl-terminal transactivation domain of Vmw65 from herpes simplex virus type 1 Journal of Biological Chemistry, 1992, 267, 1411-1414.	3.4	85
157	Enzymic and nonenzymic properties of human beta-thrombin Journal of Biological Chemistry, 1988, 263, 3576-3581.	3.4	30
158	The role of calcium ions in factor X activation by thrombin E192Q Journal of Biological Chemistry, 1992, 267, 6970-6976.	3.4	39
159	Characterization of Binding between the Chemokine Eotaxin and Peptides Derived from the Chemokine Receptor CCR3. Journal of Biological Chemistry, 2000, 275, 27250-27257.	3.4	53
160	Activation of human blood coagulation factor XI independent of factor XII Journal of Biological Chemistry, 1991, 266, 7353-7358.	3.4	367
161	Macrocyclic inhibitors of serine proteases. Advances in Amino Acid Mimetics and Peptidomimetics, 1997, , 41-76.	0.3	8
162	Characterization of binding between the chemokine eotaxin and peptides derived from the chemokine receptor CCR3. Journal of Biological Chemistry, 2000, 275, 27250-7.	3.4	51
163	A 20-Kilodalton N-Terminal Fragment of the D15 Protein Contains a Protective Epitope(s) against <i>Haemophilus influenzae</i> Type a and Type b. Infection and Immunity, 1998, 66, 3349-3354.	2.2	29

#	Article	IF	CITATIONS
164	Plasmid RK2 toxin protein ParE: purification and interaction with the ParD antitoxin protein. Journal of Bacteriology, 1996, 178, 1420-1429.	2.2	84
165	NonO, a Non-POU-Domain-Containing, Octamer-Binding Protein, Is the Mammalian Homolog of <i>Drosophila nonA</i> ^{diss} . Molecular and Cellular Biology, 1993, 13, 5593-5603.	2.3	55
166	Dynamics Govern Specificity of a Protein-Protein Interface: Substrate Recognition by Thrombin. PLoS ONE, 2015, 10, e0140713.	2.5	24
167	Affinity Tags for Protein Purification. Current Protein and Peptide Science, 2020, 21, 821-830.	1.4	31
168	Immuno-chromatographic Analysis for HPV-16 and 18 E7 Proteins as a Biomarker of Cervical Cancer Caused by Human Papillomavirus. Bulletin of the Korean Chemical Society, 2009, 30, 2999-3005.	1.9	4
170	Site-Specific Cleavage of Fusion Proteins. , 2008, 421, 211-228.		2
171	Recombinant Protein Techniques. , 1996, , 385-430.		0
172	Characteristic features of specific fermentative function of thrombin and it's connection with the structure. Biopolymers and Cell, 1996, 12, 5-15.	0.4	0
173	Protein C: Physiologie, Biochemie und Molekularbiologie., 1999,, 327-340.		0
174	Protein Expression via the Molecular Chaperone ClpL. Journal of Microbial & Biochemical Technology, 2016, 08, .	0.2	0
175	Low-molecular-weight peptides with potential cardiovascular regulatory functions from Atlantic salmon skin. International Journal of Food Engineering, 2020, 16, .	1.5	0
176	Expressing Cloned Genes for Protein Production, Purification, and Analysis. Cold Spring Harbor Protocols, 2021, 2021, pdb.top102129.	0.3	5
177	Direct N- or C-Terminal Protein Labeling Via a Sortase-Mediated Swapping Approach. Bioconjugate Chemistry, 2021, 32, 2397-2406.	3.6	4
178	Affinity Tags in Protein Purification and Peptide Enrichment: An Overview. Methods in Molecular Biology, 2021, 2178, 107-132.	0.9	14
180	McrB: a prokaryotic protein specifically recognizing DNA containing modified cytosine residues. EMBO Journal, 1995, 14, 2661-9.	7.8	23
181	Recombinant human protein C derivatives: altered response to calcium resulting in enhanced activation by thrombin. EMBO Journal, 1990, 9, 2367-73.	7.8	17
182	Thrombin alters the synthesis and processing of CYR61/CCN1 in human corneal stromal fibroblasts and myofibroblasts through multiple distinct mechanisms. Molecular Vision, 2020, 26, 540-562.	1,1	0
183	Controlled Decomposable Hydrogel Triggered with a Specific Enzyme. ACS Omega, 2022, 7, 3254-3261.	3.5	3

#	ARTICLE	IF	CITATIONS
184	Screening of the Promising Direct Thrombin Inhibitors from Haematophagous Organisms. Part I: Recombinant Analogues and Their Antithrombotic Activity In Vitro. Biomedicines, 2022, 10, 11.	3.2	4
185	Control of cell surface expression of GABAA receptors by a conserved region at the end of the N-terminal extracellular domain of receptor subunits. Journal of Biological Chemistry, 2022, 298, 102590.	3.4	1
186	Improving Stability Enhances In Vivo Efficacy of a PCSK9 Inhibitory Peptide. Journal of the American Chemical Society, 2022, 144, 19485-19498.	13.7	0
187	Crystallographic Fragment Screening on the <i>Shigella</i> Type III Secretion System Chaperone IpgC. ACS Omega, 2023, 8, 46051-46065.	3.5	0